Skip to main content
Premium Trial:

Request an Annual Quote

ActivX and Pfizer Expand Proteomics, Drug Discovery Deal

NEW YORK, March 14 (GenomeWeb News) - ActivX, a subsidiary of Tokyo-based Koran Pharmaceutical, said today that it has renewed its agreement with Pfizer to encompass discovery to developmental stage projects across multiple research sites of Pfizer's Global Research and Development organization.


Under the terms of the agreement, ActivX will apply its chemical technologies and high-throughput protein analysis to a number of Pfizer programs spanning drug discovery, polemic profiling, compound selectivity and biological activity, and mechanisms of toxicity.


Financial terms of this transaction include an upfront technology access fee along with research support payments by Pfizer.


ActivX and Pfizer began their collaboration in February 2005.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.